In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 9, 2001, Pages 2495-2501

  Chin, R ^a   Shaw, T ^a   Torresi, J ^a   Sozzi, V ^a   Trautwein, C ^a   Bock, T ^a   Manns, M ^a   Isom, H ^a   Furman, P ^a   Locarnini, S ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2' FLUORO 5 METHYL BETA LEVO ARABINOFURANOSYLURACIL; ADEFOVIR; BETA DEXTRO 2,6 DIAMINOPURINE DIOXOLANE; DNA POLYMERASE; FAMCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CROSS RESISTANCE; CYTOTOXICITY; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DIOXOLANES; DRUG RESISTANCE, MICROBIAL; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, SITE-DIRECTED; PHOSPHONIC ACIDS; PURINE NUCLEOSIDES; TRANSFECTION; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 17944372114     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.9.2495-2501.2001     Document Type: Article

References (48)

1. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
2. Inhibition of hepatitis B virus by a novel L-nucleoside 2′-fluoro-5-methyl-β-L-arabinofuranosyl uracil
3. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
4. Metabolism in human cells of the D and L enantiomers of the carbocyclic analog of 2′-deoxyguanosine: Substrate activity with deoxycytidine kinase, mitochondrial deoxyguanosine kinase, and 5′-nucleotidase
5. A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly
6. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent
7. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection
8. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir
9. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro
10. Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity
11. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus
12. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus
13. Resistance of hepatitis B virus to antiviral drugs: Current aspects and directions for future investigation
14. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B
15. Lamivudine as initial treatment for chronic hepatitis B in the United States
16. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
17. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection
18. Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants
19. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure
20. Lamivudine. A review of its therapeutic potential in chronic hepatitis B
21. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: A novel system for screening potential inhibitors of HBV replication
22. A one-year trial of lamivudine for chronic hepatitis B
23. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infected chinese: A viral dynamics study
24. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
25. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
26. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
27. Hepatitis B infection: Pathogenesis and management
28. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
29. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro
30. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
31. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B
32. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
33. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
34. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
35. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
36. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
37. Hepatitis B virus biology
38. Generation of replication-competent hepatitis B virus nucleocapsids in insect cells
39. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
40. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients
41. Combination therapy for chronic hepatitis B: The path forward?
42. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation
43. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
44. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
45. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
46. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance
47. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
48. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir